Interaction of Sulfonylureas with Liver Uptake Transporters OATP1B1 and OATP1B3

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Basic & Clinical Pharmacology & Toxicology

• Publication date

  2018-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/bcpt.12992PMID 29498478
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future

  2015cited by this paper
• The influence of herbal medicine ursolic acid on the uptake of rosuvastatin mediated by OATP1B1*1a and *5

  2014cited by this paper
• OATP1B3 Is Expressed in Pancreatic β-Islet Cells and Enhances the Insulinotropic Effect of the Sulfonylurea Derivative Glibenclamide

  2014cited by this paper
• Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications

  2014cited by this paper
• Interaction of digitalis-like compounds with liver uptake transporters NTCP, OATP1B1, and OATP1B3.

  2014cited by this paper
• Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.

  2013cited by this paper
• The Influence of Oral Antidiabetic Drugs on Cellular Drug Uptake Mediated by Hepatic OATP Family Members

  2013cited by this paper
• Management of Cardiovascular Disease Risk Factors in Older Adults with Type 2 Diabetes Mellitus: 2002–2012 Literature Review

  2013cited by this paper
• Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide

  2013cited by this paper
• Steroid hormones specifically modify the activity of organic anion transporting polypeptides.

  2012cited by this paper
• Characterization of Ursodeoxycholic and Norursodeoxycholic Acid as Substrates of the Hepatic Uptake Transporters OATP1B1, OATP1B3, OATP2B1 and NTCP

  2012cited by this paper
• Management of Dyslipidemias in the Presence of the Metabolic Syndrome or Type 2 Diabetes

  2012cited by this paper
• Oral Antidiabetic Agents

  2012cited by this paper
• Sodium fluorescein is a probe substrate for hepatic drug transport mediated by OATP1B1 and OATP1B3.

  2011cited by this paper
• Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions.

  2011cited by this paper
• Clinical Importance of OATP 1 B 1 and OATP 1 B 3 in Drug Drug Interactions

  2011cited by this paper
• Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1

  2010cited by this paper
• Membrane transporters in drug development

  2010cited by this paper
• Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms

  2010cited by this paper
• Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin

  2008cited by this paper
• The role of hepatic transporters in drug elimination

  2008cited by this paper
• The Effect of Herbal Medicine Baicalin on Pharmacokinetics of Rosuvastatin, Substrate of Organic Anion‐transporting Polypeptide 1B1

  2008cited by this paper
• Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family

  2008cited by this paper
• Substrate-Dependent Drug-Drug Interactions between Gemfibrozil, Fluvastatin and Other Organic Anion-Transporting Peptide (OATP) Substrates on OATP1B1, OATP2B1, and OATP1B3

  2007cited by this paper
• Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil

  2007cited by this paper
• [Sitagliptin. Dipeptidylpeptidase 4 inhibitor for patients with diabetes mellitus type 2].

  2007cited by this paper
• Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.

  2006cited by this paper
• Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.

  2006cited by this paper
• the Effect of

  2004cited by this paper
• Cardiovascular complications of diabetes: prevention and management.

  2003cited by this paper
• Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney.

  2002cited by this paper
• Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver.

  2001cited by this paper
• Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2.

  2001cited by this paper
• High-level expression of human inducible nitric oxide synthase in Chinese hamster ovary cells and characterization of the purified enzyme.

  1996cited by this paper
• Comparative Tolerability Profiles of Oral Antidiabetic Agents

  1994cited by this paper
• Increased synthesis of secreted proteins induces expression of glucose-regulated proteins in butyrate-treated Chinese hamster ovary cells.

  1989cited by this paper
• Clinical Pharmacology of Oral Antidiabetic Agents

  1977cited by this paper
• Clinical pharmacology of oral antidiabetic agents (first of two parts).

  1977cited by this paper
• Binding of sulfonylureas to serum proteins.

  1972cited by this paper
• 0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(5):2078–2084 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-031907 Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels

  year unknowncited by this paper

• Discovery of novel and potent NLRP3 inflammasome inhibitors with new lipophilic moieties.

  2025cites this paper
• Pharmacokinetics and lipid-lowering efficacy affected by polymorphisms in genetic variability in statin therapy

  2025cites this paper
• Comparisons of pharmacokinetics of glimepiride in combination with Ojeok-san versus glimepiride alone: an open-label, one-sequence, two-treatment controlled clinical study

  2025cites this paper
• In vitro-in vivo scaling of cytochrome P450-mediated metabolic clearance using a relative activity factor approach.

  2025cites this paper
• An Overview of the Pharmacogenetics of Sulfonylurea in Type 2 Diabetes Mellitus

  2024cites this paper
• Rat PermQ: A permeability- and perfusion-based physiologically based pharmacokinetic model for improved prediction of drug concentration-time profiles in rat.

  2024cites this paper
• Investigation of drug-polymer miscibility and design of ternary solid dispersions for oral bioavailability enhancement by hot melt extrusion

  2023cites this paper
• When the same treatment has different response: The role of pharmacogenomics in statin therapy.

  2023cites this paper
• Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects

  2023cites this paper
• Mitochondrion-Targeted NIR Therapeutic Agent Suppresses Melanoma by Inducing Apoptosis and Cell Cycle Arrest via E2F/Cyclin/CDK Pathway

  2022influential citation
• SLCO1B1 c.521T>C gene polymorphism decreases hypoglycemia risk in sulfonylurea-treated type 2 diabetic patients

  2022cites this paper
• Evaluating gliclazide for the treatment of type 2 diabetes mellitus

  2022influential citation
• Potential Herb–Drug Interactions in the Management of Age-Related Cognitive Dysfunction

  2021cites this paper
• Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas

  2021cites this paper
• Genome-wide meta-analysis identifies genetic variants associated with glycemic response to sulfonylureas

  2021influential citation
• Genome-wide meta-analysis identifies genetic variants associated with glycemic response to sulfonylureas

  2021influential citation
• Genome-wide meta-analysis identifies genetic variants associated with glycemic response to sulfonylureas

  2021influential citation
• Effect of Nigella sativa oil on pharmacokinetics and pharmacodynamics of gliclazide in rats

  2021cites this paper
• Interaction between Omeprazole and Gliclazide in Relation to CYP2C19 Phenotype

  2021influential citation
• Genome-Wide Meta-Analysis Identifies the Organic Anion-Transporting Polypeptide Gene SLCO1B1 and Statins as Modifiers of Glycemic Response to Sulfonylureas

  2021cites this paper
• Hepatic transporter‐mediated pharmacokinetic drug–drug interactions: Recent studies and regulatory recommendations

  2021cites this paper
• Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics

  2020influential citation
• Hypoglycemia and Glycemic Control With Glyburide in Women With Gestational Diabetes and Genetic Variants of Cytochrome P450 2C9 and/or OATP1B3

  2020influential citation
• Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom

  2020cites this paper
• OATP1B3 (699G>A) and CYP2C9*2, *3 significantly influenced the transport and metabolism of glibenclamide and glipizide

  2018cites this paper